News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
484,503 Results
Type
Article (8028)
Company Profile (140)
Press Release (476334)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166752)
Career Advice (306)
Deals (25741)
Drug Delivery (7)
Drug Development (52881)
Employer Resources (14)
FDA (9760)
Job Trends (8577)
News (238202)
Policy (17906)
Tag
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (4)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (487)
Accelerated approval (24)
ADA (18)
Adcomms (1)
Allergies (96)
Alliances (33161)
ALS (104)
Alzheimer's disease (975)
Antibody-drug conjugate (ADC) (262)
Approvals (10370)
Artificial intelligence (319)
ASCO (159)
Autoimmune disease (205)
Automation (28)
Bankruptcy (262)
Best Places to Work (6963)
BIO (36)
BIOSECURE Act (1)
Biosimilars (108)
BioSpace Insights (17)
Biotechnology (88)
Bladder cancer (138)
Brain cancer (28)
Breast cancer (507)
Cancer (3632)
Cardiovascular disease (217)
Career advice (247)
Career pathing (1)
CAR-T (172)
Celiac Disease (1)
Cell therapy (476)
Cervical cancer (34)
Clinical research (47854)
Collaboration (1240)
Commercialization (3)
Compensation (1452)
Complete response letters (34)
COVID-19 (756)
CRISPR (63)
C-suite (739)
Cystic fibrosis (85)
Data (5630)
Denatured (4)
Depression (102)
Dermatology (60)
Diabetes (341)
Diagnostics (4178)
Digital health (37)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (154)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (163)
Earnings (73698)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (87596)
Executive appointments (699)
FDA (12373)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (18)
Frontotemporal dementia (23)
Funding (911)
Gene editing (125)
Generative AI (9)
Gene therapy (315)
GLP-1 (289)
Government (950)
Grass and pollen (2)
Guidances (281)
Healthcare (9327)
Hematology (94)
HIV (52)
Huntington's disease (22)
IgA nephropathy (64)
Immunology and inflammation (98)
Immuno-oncology (56)
Indications (156)
Infectious disease (944)
Inflammatory bowel disease (126)
Inflation Reduction Act (4)
Influenza (84)
Intellectual property (253)
Interviews (42)
IPO (12390)
IRA (2)
Job creations (1970)
Job search strategy (236)
JPM (1)
Kidney cancer (16)
Labor market (1)
Layoffs (62)
Legal (5209)
Licensing (7)
Liver cancer (44)
Longevity (15)
Lung cancer (505)
Lymphoma (250)
Machine learning (27)
Management (3)
Manufacturing (528)
Marketing (8)
MASH (118)
Medical device (8651)
Medtech (8791)
Mergers & acquisitions (14381)
Metabolic disorders (704)
mRNA (53)
Multiple sclerosis (102)
NASH (4)
Neurodegenerative disease (220)
Neuropsychiatric disorders (38)
Neuroscience (1819)
NextGen: Class of 2026 (3154)
Non-profit (846)
Now hiring (1)
Obesity (223)
Opinion (10)
Ovarian cancer (158)
Pain (170)
Pancreatic cancer (195)
Parkinson's disease (201)
Partnered (12)
Patents (472)
Patient recruitment (503)
Peanut (31)
People (41231)
Pharmaceutical (30)
Pharmacy benefit managers (8)
Phase 1 (15461)
Phase 2 (21371)
Phase 3 (14395)
Pipeline (7262)
Policy (18)
Postmarket research (1572)
Preclinical (6537)
Press Release (34)
Prostate cancer (189)
Psychedelics (7)
Radiopharmaceuticals (189)
Rare diseases (569)
Real estate (3021)
Recruiting (6)
Regulatory (14809)
Reports (20)
Research institute (582)
Resumes & cover letters (46)
Rett syndrome (41)
RNA editing (5)
RSV (48)
Schizophrenia (99)
Series A (152)
Series B (121)
Service/supplier (5)
Sickle cell disease (62)
Spinal muscular atrophy (88)
Sponsored (5)
Startups (2021)
Stomach cancer (3)
Supply chain (50)
Vaccines (318)
Venture capital (17)
Weight loss (73)
Women's health (78)
Date
Today (49)
Last 7 days (421)
Last 30 days (1626)
Last 365 days (19074)
2026 (12124)
2025 (19255)
2024 (22992)
2023 (26538)
2022 (34587)
2021 (37170)
2020 (33479)
2019 (23276)
2018 (17471)
2017 (18767)
2016 (17920)
2015 (24263)
2014 (21679)
2013 (18135)
2012 (20221)
2011 (20441)
2010 (20332)
Location
Africa (228)
Alabama (73)
Alaska (2)
Arizona (300)
Arkansas (11)
Asia (17880)
Australia (2097)
California (11916)
Canada (3128)
China (518)
Colorado (482)
Connecticut (408)
Delaware (208)
Europe (24619)
Florida (1783)
Georgia (376)
Hawaii (3)
Idaho (46)
Illinois (695)
India (48)
Indiana (314)
Iowa (14)
Japan (398)
Kansas (101)
Kentucky (30)
Louisiana (26)
Maine (26)
Maryland (1198)
Massachusetts (7833)
Michigan (307)
Minnesota (559)
Mississippi (4)
Missouri (80)
Montana (20)
Nebraska (11)
Nevada (114)
New Hampshire (60)
New Jersey (2615)
New Mexico (12)
New York (2813)
North Carolina (1269)
North Dakota (4)
Northern California (5966)
Ohio (276)
Oklahoma (14)
Oregon (16)
Pennsylvania (2246)
Puerto Rico (20)
Rhode Island (30)
South America (406)
South Carolina (76)
South Dakota (1)
Southern California (4947)
Tennessee (119)
Texas (1930)
United States (38722)
Utah (358)
Vermont (1)
Virginia (153)
Washington D.C. (38)
Washington State (923)
West Virginia (1)
Wisconsin (73)
484,503 Results for "allakos inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Layoffs
Allakos Will Axe 75% of Workforce, Drop Hives Candidate
Following disappointing clinical trial results for AK006, Allakos will cut its workforce down to under 20 employees as it explores strategic alternatives.
January 27, 2025
·
1 min read
·
Angela Gabriel
Business
Allakos Provides Business Update and Reports First Quarter 2024 Financial Results
Allakos Inc., a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, provided a business update and reported financial results for the first quarter ended March 31, 2024.
May 9, 2024
·
8 min read
Drug Development
Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria
Allakos Inc. announced that the first patient with chronic spontaneous urticaria has been dosed in a randomized, double-blind, placebo-controlled Phase 1 trial of AK006.
May 28, 2024
·
5 min read
Press Releases
Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share
April 3, 2025
·
4 min read
Press Releases
Allakos Provides Business Update and Reports Fourth Quarter 2024 Financial Results
March 13, 2025
·
6 min read
Biotech Bay
Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced the publication of new scientific results in Allergy.
February 12, 2024
·
6 min read
Business
Allakos Appoints Rand Sutherland and Dolca Thomas to its Board of Directors
Allakos Inc. announced the appointment of Rand Sutherland, M.D. and Dolca Thomas, M.D. to the Allakos board of directors.
August 2, 2023
·
4 min read
Business
Allakos Appoints Neil Graham to its Board of Directors
Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced the appointment of Neil Graham, M.D. to the Allakos board of directors.
August 30, 2023
·
3 min read
Biotech Bay
Allakos Announces a Restructuring to Focus on Development of AK006
Allakos Inc. today announced a restructuring to reduce costs and to focus on AK006 clinical development and additional preclinical programs. As a result, the Company’s cash runway is expected to extend into mid-2026.
January 16, 2024
·
8 min read
Business
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2023.
March 14, 2024
·
9 min read
1 of 48,451
Next
